Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Welte

Showing results (51-60 of 148) with videos related to

Pageof 15
Sort By:
Stem Cell Research & Therapy|February 6, 2021
NAMPT/SIRT2-mediated inhibition of the p53-p21 signaling pathway is indispensable for maintenance and hematopoietic differentiation of human iPS cellsYun Xu, Masoud Nasri, Benjamin Dannenmann, et al.
British Journal of Haematology|April 9, 2005
Heterogeneous expression pattern of pro- and anti-apoptotic factors in myeloid progenitor cells of patients with severe congenital neutropenia treated with granulocyte colony-stimulating factorGunnar Cario, Julia Skokowa, Zheng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Münster Trial NHL-BFM 95Kathrin Seidemann, Martin Zimmermann, Marion Book, et al.
Stem Cell Research & Therapy|October 20, 2023
Correction: NAMPT/SIRT2-mediated inhibition of the p53-p21 signaling pathway is indispensable for maintenance and hematopoietic differentiation of human iPS cellsYun Xu, Masoud Nasri, Benjamin Dannenmann, et al.
Annals of Hematology|December 15, 2016
GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signalingCorinna Koch, Bardia Samareh, Tatsuya Morishima, et al.
Journal of Pediatric Hematology/Oncology|May 17, 2011
Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in childrenCarolin Hartmann, Peter Weinel, Hansjörg Schmid, et al.
British Journal of Haematology|January 20, 2021
Nicotinamide (vitamin B3) treatment improves response to G-CSF in severe congenital neutropenia patientsEkaterina Deordieva, Oksana Shvets, Kirill Voronin, et al.
Annals of the New York Academy of Sciences|February 22, 2020
New insights into the pathomechanism of cyclic neutropeniaPerihan Mir, Maksim Klimiankou, Betuel Findik, et al.
British Journal of Haematology|July 9, 2003
Expression and structural analysis of glucocorticoid receptor isoform gamma in human leukaemia cells using an isoform-specific real-time polymerase chain reaction approachCarmela Beger, Katrin Gerdes, Melchior Lauten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinomaCarmela Beger, Marco Ramadani, Stephan Meyer, et al.
Pageof 15

Showing results (51-60 of 148) with videos related to

Sort By:
Pageof 15
Stem Cell Research & Therapy|February 6, 2021
NAMPT/SIRT2-mediated inhibition of the p53-p21 signaling pathway is indispensable for maintenance and hematopoietic differentiation of human iPS cellsYun Xu, Masoud Nasri, Benjamin Dannenmann, et al.
British Journal of Haematology|April 9, 2005
Heterogeneous expression pattern of pro- and anti-apoptotic factors in myeloid progenitor cells of patients with severe congenital neutropenia treated with granulocyte colony-stimulating factorGunnar Cario, Julia Skokowa, Zheng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Münster Trial NHL-BFM 95Kathrin Seidemann, Martin Zimmermann, Marion Book, et al.
Stem Cell Research & Therapy|October 20, 2023
Correction: NAMPT/SIRT2-mediated inhibition of the p53-p21 signaling pathway is indispensable for maintenance and hematopoietic differentiation of human iPS cellsYun Xu, Masoud Nasri, Benjamin Dannenmann, et al.
Annals of Hematology|December 15, 2016
GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signalingCorinna Koch, Bardia Samareh, Tatsuya Morishima, et al.
Journal of Pediatric Hematology/Oncology|May 17, 2011
Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in childrenCarolin Hartmann, Peter Weinel, Hansjörg Schmid, et al.
British Journal of Haematology|January 20, 2021
Nicotinamide (vitamin B3) treatment improves response to G-CSF in severe congenital neutropenia patientsEkaterina Deordieva, Oksana Shvets, Kirill Voronin, et al.
Annals of the New York Academy of Sciences|February 22, 2020
New insights into the pathomechanism of cyclic neutropeniaPerihan Mir, Maksim Klimiankou, Betuel Findik, et al.
British Journal of Haematology|July 9, 2003
Expression and structural analysis of glucocorticoid receptor isoform gamma in human leukaemia cells using an isoform-specific real-time polymerase chain reaction approachCarmela Beger, Katrin Gerdes, Melchior Lauten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinomaCarmela Beger, Marco Ramadani, Stephan Meyer, et al.
Pageof 15